International Conference on Integrated Care 23rd till the 25th of May 2016 in Barcelona.

This conference will bring together researchers, clinicians and managers from around the world who are engaged in the design and delivery of integrated health and social care.

Together with Dr. Hanneke Molema, TNO; Dr. Arianne Elissen, Maastricht University; Dr. Nick Guldemond, University Medical Centre Utrecht, Evert Jan Hoijtink, CEO of Portavita will give a workshop about Digital Health Innovations for Personalized Integrated Care. During this workshop Evert Jan Hoijtink, will explain the Patient Centered Integrated Care Treatment and Prevention Programs  (Tuesday 24th of May between 11.30AM-1.00PM).

Agenda ICIC 2016

Solution

Portavita Integrated Care System (ICS), our web-based solution for prevention, treatment and healthcare management in a coordinated way. The patients and all involved practitioners use the underlying Electronic Health Record.

We provide a co-operation platform to support primary processes, patient self-management and healthcare organisations with their reporting, research and financial-data needs. Our solution has an integrated messaging system, an authorisation and workflow engine and e-Learning modules.

Input of leading medical professionals and their patients is the basis for the current modules of the system: Anticoagulation, Asthma/COPD, Cardiovascular Risk Management, Diabetes and Elderly Care

Vision

Health of people requires good cooperation between patients and their involved practitioners, irrespective of time and place.

Evidence

Portavita solutions support thousands of medical organisations since 2002. Currently our Dutch, German, Russian and South American customers support over 500.000 patients. They work in a multi-organisational and multi-disciplinary setting. Within these healthcare organisations, 10.000 medical professionals and over 100.000 participating self-management patients use our online solution on a daily basis. These organisations achieve over 80% of patients, treated with Oral AC, to be in their therapeutic range (TTR). In most countries worldwide this is on average 10% lower*. Many countries are performing even seriously lower at higher cost per monitored patient. *German study of Dr. Koerte, a German study of dr. Hortkotte and a large retrospective study of Dr. Boulanger in the United States. 

Partner

Amongst others our partners are Philips Healthcare, Roche Diagnostics and Deutsche Telekom Health Solutions.

Research & Innovation

Portavita supports an eco system of building medical protocol supportive software, gathering results of the medical treatments and sharing this medical data for Research and Analytics. The improvements and refinements are again input for the medical protocols.

An overview:

  • COMMODITY12

A European Union (EU) innovation project in which continuous monitoring devices are connected to the Portavita ICS for diabetes. (www.commodity12.eu)

  • AXLE

In this EU project the focus point is analytics on big medical data with special attention to data protection, patient privacy and scalability (www.axleproject.eu)

  • thrombEVAL

A project to research the applicability of the Dutch based anticoagulation solution for Germany. Munzel T, Wild PS. Quality of oral anticoagulation with phenprocoumon in regular medical care and its potential for improvement in a telemedicine-based coagulation service – results from the prospective, multi-center, observational cohort study thrombEVAL. European Journal of Preventive Cardiology, 2014.

  • Near Patient Testing by care takers in elderly homes

Study into the effectiveness, safety and well-considered introduction of Near-Patient Testing in elderly and nursing homes in The Netherlands. Verstappen WHJM, Land RP van ‘t.Near-Patient Testing (NPT) of coagulation time in health care institutions.

  • Reasons and Barriers for Using a Patient Portal

Study shows the reasons and barriers of patients with diabetes for using a Web portal with access to their own personal health record. Ronda MCM, Dijkhorst-Oei L, Rutten GEHM. Reasons and Barriers for Using a Patient Portal: Survey Among Patients With Diabetes Mellitus. Journal of Medical Internet Research, 2014.

 

Quality and privacy

  • Portavita is ISO 13485:2003 certified since 22 January 2014.
  • Portavita is compliant with the European medical device directive 93/42/EEC (CE label)
  • Portavita complies with the Dutch and German Personal Data Protection Acts.
  • For the Russian market we have a Roszdravnazor registration certificate.

 

Business Model

Together with our local partner we organise a total solution, including medical care providers responsible for the treatment, devices, medication, reimbursement, Standard Operation Procedures, education and ICT. Portavita offers its platform on a “pay per use” basis. One-time investments are related to translation, local hosting, training and potential adaption to the local protocols.
 

We look for Partners

Do you see an opportunity for improved patient treatment, a business case, using the Portavita Integrated Care System? Our Platform can be an add-on for applications that you already use, or it might offer you the possibility to collaborate on a specific clinical picture. Or perhaps it could support you in the improvement of the treatment of patients who live in rural areas. Just feel free to contact us to discuss how we can help realise your goals.

Contact

Portavita

Evert Jan Hoijtink Founder & CEO
Oostenburgervoorstraat 83a
1018MP Amsterdam
The Netherlands
+31 652 523 541 [mobile]
e.j.hoijtink@portavita.eu
www.portavita.com

 

The Foundation’s Administrative Office is located in Oxfordshire in the U.K.

7200 The Quorum
Oxford Business Park North, Garsington Road
Oxford OX4 2JZ
United Kingdom
+44 (0) 1865487229 [tel]
info@integratedcarefoundation.org
integratedcarefoundation.org